Abstract: Cosmetic/pharmaceutical compositions useful for regulating the size of sebaceous glands and, in particular, for inhibiting sebum production, or for treating pathologies entailing an overproduction of sebum, or for treating greasy skin and/or a scalp prone to dandruff, contain thus effective amounts of at least one activator of PPAR type receptors.

Abstract: Sprayable pharmaceutical compositions suited for improved transdermal penetration contain a) at least one bioactive agent, notably at least one derivative of vitamin D, (b) at least one volatile silicone and c) a non-volatile oily phase, formulated into d) a pharmaceutically acceptable vehicle therefor.

Abstract: Novel pharmaceutical/cosmetic compositions contain at least one biaromatic ligand activator of a PPAR? receptor, such biaromatic ligand having the structural formula (I): and are well suited, inter alia, for regulating and/or restoring skin lipid metabolism, for treating a wide variety of dermatological afflictions, and for preventing and/or treating the signs of aging and/or dry skin.

Abstract: Novel ligand compounds having the structural formula (I): and the salts and optical/geometrical isomers thereof are suited for formulation into pharmaceutical compositions useful in human or veterinary medicine, or, alternatively, into cosmetic compositions.

Abstract: Novel ligand compounds that activate RAR receptors have the following structural formula (I): and are suited for formulation into pharmaceutical compositions useful in human or veterinary medicine, or, alternatively, into cosmetic compositions.

Abstract: Topically applicable cosmetic/pharmaceutical oil-in-water emulsions, well suited for treating or caring for the skin and/or superficial body growths therefrom, include a discontinuous fatty phase dispersed in a continuous aqueous phase and comprise an effective amount of at least one biologically active agent (A) and an effective amount of an emulsifying system (B) therefor, the at least one biologically active agent (A) being non-solubilized therein in micronized particulate state, at least 80%, numerically, of the micronized particles having diameters ranging from 1 to 10 ?m and at least 50%, also numerically, having diameters of less than 5 ?m.

Abstract: Compositions in the form of a spray contain a pharmaceutical active agent, at least one volatile silicone and a non-volatile oily phase, formulated into a physiologically acceptable medium, are well suited for improved transdermal administration in cosmetics and dermatology.

Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.

Abstract: The present invention provides for a method of using adapalene for the maintenance theray of acne vulgaris to prevent acne recurrence or reduce the severity of the acne recurrence.

Abstract: Polynucleotide probes relating to the FANCC, DAD1, GRIM19 and HADHII genes are useful for characterizing biological samples and for identifying compounds suited for the treatment of psoriasis.

Abstract: Novel compounds that are ligands of the LXR receptors have the following structural formula (I): and are formulated into pharmaceutical compositions useful in human or veterinary medicine, or alternatively into cosmetic compositions.

Abstract: Novel compounds which modulate PPAR-type receptors have the following general formula (I): and are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology and in the fields of cardiovascular diseases, immune diseases and/or diseases linked to lipid metabolism), or are formulated into cosmetic compositions.

Abstract: Novel compounds which modulate PPAR-type receptors have the following general formula (I): and are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology and in the fields of cardiovascular diseases, immune diseases and/or diseases linked to lipid metabolism), or are formulated into cosmetic compositions.

Abstract: Topically applicable, stable and non-irritating aqueous-alcoholic cosmetic/dermatological gels suited for cutaneous depigmentation contain water, at least one alcohol, at least one gelling agent, at least one phenolic compound, at least one retinoid, and, optionally, at least one sunscreen, formulated into a topically applicable, physiologically acceptable medium therefor.

Abstract: Cosmetic/dermatological compositions useful for the treatment of a variety of dermatological conditions, including keratinization disorders, acne, eczema, psoriasis, etc., comprise an invert emulsion containing at least one active agent sensitive to the presence of water, notably a derivative of vitamin D, and solubilized in a glycolic or hydroglycolic dispersed hydrophilic phase, a lipophilic continuous phase and an emulsifier having an HLB ranging from 2 to 7; these invert emulsions exhibit good stability and avoid crystallization of the active agent and/or chemical degradation thereof.

Abstract: The invention relates to novel stilbene compounds having the general formula (I): as well as to pharmaceutical compositions for use in human or veterinary medicine, including dermatological, rheumatic, respiratory, cardiovascular and ophthalmic conditions and cosmetic compositions and methods of use thereof.

Abstract: The invention concerns novel diarylselenide compounds corresponding to the general formula (I) and the use thereof in pharmaceutical compositions in human or veterinary medicine (in the treatment of dermatological, rheumatic, cardiovascular and ophthalmologic pathologies in particular), or in cosmetic compositions.

Abstract: The invention concerns novel diarylselenide compounds corresponding to formula (I): and the use thereof in pharmaceutical compositions in human or veterinary medicine (in the treatment of dermatological, rheumatic, cardiovascular and ophthalmologic pathologies in particular), or in cosmetic compositions.

Abstract: Novel polycyclic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.

Abstract: Topically applicable pharmaceutical gel, cream, lotion, solution or ointment compositions contain synergistically effective amounts of a) calcitriol and b) clobetasol propionate, formulated into a topically applicable, pharmaceutically acceptable medium therefor, and are useful for the treatment of such dermatological afflictions or conditions as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic dermatitis.